On Sept 21, South Korean biotech company ATGen signed a Letter of Intent for strategic alliances with CellMark to expand in the European market with the sale and marketing of ATgen’s product NK Vue Kit. Through CellMark’s global marketing network, ATGen will roll out its NK Vue Kit, which helps to set early diagnosis of Cancer. Under this LOI agreement, ATGen can expect to accelerate overseas expansion and access local market research worldwide. CellMark recently expanded its business to include also Med Tech products and services. CellMark Medical ATGen Co. Ltd. is a biotech company that manufactures and supplies proteins and antibodies worldwide.
NK Vue Kit
In the average human body, there are more than 5,000 abnormal cells such as cancer cells, growing and dying every day. The Natural Killer cell is the only cell that recognizes and attacks cancer cells, which can inhibit from the proliferation of cancer cells and prevent from recurrence. NK Vue is an analysis kit to check activity of Natural Killer cell which can be regarded as an anti-tumor immunity cell. The test can help assess your immune system’s ability to fight disease, providing an early warning signal to trigger additional testing or lifestyle changes.
ATGen Co Ltd’s full press release:
“ATgen announced that ATgen signed a LOI for strategic alliances with CellMark for the sale and marketing of NK Vue Kit on 21st Sep 2016. Both agreed to co-develop a global market expansion and increase sales through CellMark global marketing network. NK Vue is a analysis kit to check activity of Natural Killer cell which can be regarded as an antitumor immunity cell. CellMark, which was founded in Sweden in 1984, is a distributer of raw materials and supply-chain service provider. The annual trade volume reaches 6 million tons, and the Group sales is about 3 billion US dollars. CellMark is a truly global company with a network of 70 offices in 30 countries. Recently, the company leveraged it’s strong marketing and distribute platform expanding present business of Paper, Pulp, Packaging, Recycling, Chemicals, Metals and Energy to also include Bio Heath care and Med Tech. Under this LOI agreement with CellMark, ATgent can expect to accelerate overseas expansion by upgrading global marketing capacity. Local market research can be supported by using CellMark global network, which can also enable to sell NK Vue kit without any direct distributor management. CellMark platform also includes screening services to qualify local distributor and recruit a local employee and also can bring a great momentum to enter new market. CEO of ATgen Mr. Park said, “We could establish a bridgehead to secure an advance foundation for expansion toward unexplored field of Europe and South America. We will pioneer new market together with CellMark.”
CellMark enter into new business area and will together with healthcare entrepreneurs offer products, services and solutions that will improve health and wellbeing globally. CellMark Medical, will enable innovative, small- and mid-sized, medical technology companies to accelerate their growth in emerging markets, predominantly in the Asia Pacific region, and offer an innovative and cost-effective IT platform to our MedTech partners and hospitals for them to do business on.
CellMark’s global presence in combination with the IT system provide a unique opportunity to add value to the global healthcare market in terms of open up new markets, offer distribution of products, consumables, chemicals and in the future drugs at significant lower costs than offered today and with better transparency between the product owners and the end users. The significantly improved transparency offers the product owners unprecedented insights into market needs for their product development.
CellMark Medical provide a global approach to its partners when it comes to product licenses and by that offer a new approach to a global issue in regards to product control. Our partners will have full control of their products on all markets over their life time. The opportunity for the product owners to protect their intellectual property, manage transactions in their home markets, improve data for their product development and at the same time drive growth globally is very attractive. On the receiving end, in emerging markets, local distributers and users will have access to products they need but historically not have had access to. The cost efficient distribution model will ensure that products can be sold at an acceptable price level.
CellMark Medical, will be a solid meeting place for global entrepreneurs. Please do contact any of the team to discuss business opportunities!